Samsung BioLogics under review for pre-IPO fraud
South Korea’s Financial Supersory Service is reviewing Samsung BioLogics for potential financial fraud in the lead up to its W2.25tr ($2.0bn) IPO last year, according to a banker who worked on the listing.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts